The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Recruiting patients for rare disease trials is akin to finding a needle in a haystack, with challenges such as geographical ...

(RTTNews) - Johnson & Johnson (JNJ), Friday announced the submission of regulatory applications for Darzalex Faspro to the U.S. Food and Drug Administration, and Darzalex to the European Medicines ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

US healthcare giant Johnson & Johnson today revealed it has submitted applications with the US Food and drug Administration ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update. "Regeneron had a strong third quarter marked by 11% ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

French pharmaceutical group Sanofi experienced a profitability boom in the third ... Tzield - for type 1 diabetes -, Sarclisa (multiple myeloma) and Rezurock, used in cases of graft-versus-host ...

Sanofi will keep a significant stake in the ... with Sarclisa in the U.S. for adult patients with newly diagnosed multiple ...

PARIS (AP) — PARIS (AP) — Sanofi (SNY) on Friday reported third-quarter earnings of $3.09 billion. The company said it had net income of $1.23 per share. Earnings, adjusted for non-recurring ...